The Same But Different? An Analysis of Late-Onset Axial Spondyloarthropathy

Maguire, Sinead; O’Shea, Finbar

doi:10.1097/rhu.0000000000001700

Cited by 2 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported prevalence of LoAS within the broader AS patient population has exhibited variability, ranging from 3.5 to 9.7% across studies that employed different cut-off values such as 40, 45, or 50 years at onset 3 , 7 , 22 . In our investigation, we observed that LoAS patients accounted for 9.9% of the 2854 AS patients who received their initial TNFi treatment as part of the TURKBIO Registry.…”

Section: Discussionmentioning

confidence: 99%

“…In patients with AS, male predominance and HLA-B27 positivity tend to decrease in late onset groups 5,7 . Consistent with findings from the KOBIO Registry 19 , this study also identified a lower frequency of male patients and HLA-B27 positivity in LoAS patients who initiated their first TNFi treatment compared to YoAS patients.…”

Section: Factors Influencing Tnfi Retention In All As Patients and By...mentioning

confidence: 96%

“…Moreover, the late onset spectrum of spondyloarthritis (SpA) extends to include late onset peripheral SpA and late onset psoriatic arthritis (PsA) 3 , 5 , 6 . A recent study also explored late onset non-radiographic axial SpA (nr-AxSpA) patients 7 . There are different grouping recommendations for patients diagnosed with AS according to the age of onset of symptoms.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

Uslu,

Gulle,

Sen

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was ≥ 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset. There were 2573 patients with YoAS and 281 LoAS. Baseline disease activity measures were similar between the groups. No significant differences were seen between the two groups in response to treatment and in remaining on the first TNFi at 6, 12 and 24 months. In the LoAS group, the analysis showed that TNFi discontinuation was linked to VAS pain score (HR 1.04; 95% CI 1.01–1.06). Patient groups had similar rates of adverse events (YoAS: 8.7% vs. LoAS: 11.7%). In both biologic naive LoAS and YoAS patients, the study showed that the initial TNFi therapy was equally effective and safe.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Factors Influencing Tnfi Retention In All As Patients and By...mentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

Uslu,

Gulle,

Sen

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results

Uslu,

Gülle,

Urak

et al. 2024

Arch Rheumatol

View full text Add to dashboard Cite

Objectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS). Patients and methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as <60 years of age (n=610), and those aged ≥60 years (n=201) were recorded as elderly patients. Demographic, clinical, and laboratory characteristics, along with disease activity markers and other follow-up parameters, as well as current and prior treatments, were electronically recorded during each visit using open-source software. Results: The mean age of the elderly patients was 67±5.8 years, while the mean age of the younger patients was 49.2±10.9 years. Male predominance was lower in the older AS group compared to the younger AS group (p=0.002). During follow-up period, 397 patients (comprising 318 young and 79 elderly individuals) had a history of using at least one biological disease-modifying agent (bDMARD). There was no significant difference between the groups in terms of DMARD and bDMARD-use distributions. First tumor necrosis factor inhibitor (TNFi) retention rates were found to be similar in both groups over 10 years of follow-up. Adverse events were found to be similar in young (19.9%) and elderly (26.8%) AS patients. Conclusion: Research in the TURKBIO cohort reveals that both older and younger patients with AS exhibited similar disease activity levels with comparable treatment approaches. Moreover, the results of TNFi treatments in elderly patients were the same as those observed in younger patients, with no notable increase in safety concerns.

show abstract

The Same But Different? An Analysis of Late-Onset Axial Spondyloarthropathy

Cited by 2 publications

References 15 publications

Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results

Contact Info

Product

Resources

About